Conditioning Regimens Prior to Autologous Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Galina Dmitrievna Petrova, I.S. Monin, N.M. Zolotaikina, A.F. Sysoeva, K.A. Pekhova, E.F. Orlova, L.Yu. Maltseva, N.N. Zaguzina, O.A. Kolomeytsev, T.T. Valiev, V.V. Grishina, G.S. Tumyan,

DOI:

https://doi.org/10.21320/2500-2139-2026-19-4-443-452

AIM. To analyze the efficacy of various high-dose chemotherapy (HDCT) regimens with autologous hematopoietic stem cell transplantation (auto-HSCT) in patients with relapsed/refractory classical Hodgkin lymphoma (r/r cHL).

MATERIALS & METHODS. The study enrolled 356 r/r cHL patients treated at the NN Blokhin National Medical Cancer Research Center from 1996 to 2025. The primary refractory course was reported in 54.8 % of patients. At the time of auto-HSCT, the median age of patients was 30.6 years. Prior to auto-HSCT, most of them (51.5 %) received standard second-line polychemotherapy (PCT), whereas 48.6 % of patients were treated with targeted drugs or/and immune checkpoint inhibitors (ICIs) either as monotherapy or combined with PCT. Prior to auto-HSCT, most patients showed chemotherapy-sensitive disease (78 %). Conditioning regimens included BEAM (43 %), LEAM (35 %), as well as other regimens (Mito-L/PAM, BeEAM, BeEAC, NEAM, Mito-CBV, VpMelTBI, CEAC, CBV, and Mel) in 22 % of cases.

RESULTS. The immediate efficacy was as follows: complete remission (CR) was achieved in 68.8 % and partial remission in 10.0 % of patients, stable disease was reported in 6.5 % and relapse or progression in 14.0 % of patients. Mortality from treatment toxicity within the first year after auto-HSCT was 2.5 %. Over a 3-year period, the total cohort showed the relapse rate of 31.0 %, overall survival (OS) rate of 85.2 %, progression-free and event-free survival rates of 68.2 % and 60.0 %, respectively. The analysis of the short- and long-term outcomes in relation to HDCT regimens revealed the best rates achieved by the LEAM program. However, the multivariate regression analysis excluded the value of HDCT regimens for OS in r/r cHL. The analysis revealed such OS criteria as administration of new drugs (targeted agents or/and ICIs) prior to auto-HSCT and achieving CR at the time of auto-HSCT. By regression analysis, administration of new drugs prior to auto-HSCT reduces mortal probability by 68 %, whereas achieving CR prior to auto-HSCT improves OS rates by 59 %. In patients with CR, the 3-year OS was 94 %.

CONCLUSION. The choice of HDCT regimen had no significant effect on the OS rates. Targeted drugs or/and ICIs along with CR achieved prior to auto-HSCT significantly improve long-term outcomes of r/r cHL treatment.

  1. Лимфома Ходжкина. Клинические рекомендации. Ассоциация онкологов России, Национальное общество детских гематологов, онкологов, Российское профессиональное общество онкогематологов, Некоммерческое партнерство содействия развитию гематологии и трансплантологии костного мозга «Национальное гематологическое общество», 2024. (электронный документ) Доступно по: https://cr.minzdrav.gov.ru/view-cr/139_2. Ссылка активна на 29.05.2026. [Hodgkin Lymphoma. Clinical Guidelines. Russian Oncology Association, National Society of Pediatric Hematologists and Oncologists, Russian Society of Professional Oncohematologists, Non-Commercial Partnership for Hematology and Bone Marrow Transplantation Support “National Society of Hematologists”, 2024. (Internet) Available from: https://cr.minzdrav.gov.ru/view-cr/139_2. Accessed 29.05.2026. (In Russ)]
  2. Демина Е.А. Руководство по лечению лимфомы Ходжкина. М., 2021. [Demina E.A. Rukovodstvo po lecheniyu limfomy Khodzhkina. (Guidelines for the treatment of Hodgkin Lymphoma.) Moscow; 2021. (In Russ)]
  3. Martinez A, Bazarbachi A, Sureda A. Classical Hodgkin’s Lymphoma. The EBMT Handbook, 2024. pp. 799–808. DOI: https://doi.org/10.1007/978-3-031-44080-9_89
  4. NCCN Guidelines Hodgkin Lymphoma. Version 1.2026. Available from: https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf (accessed 11.11.2025).
  5. Greco R, Ruggeri A, McLornan DP, et al. Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations. Bone Marrow Transplant. 2025;60(11):1499–525. doi: 10.1038/s41409-025-02701-3. DOI: https://doi.org/10.1038/s41409-025-02701-3
  6. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin’s disease: Results of a BNLI randomized trial. Lancet. 1993;341(8852):1051–4. doi: 10.1016/0140-6736(93)92411-l. DOI: https://doi.org/10.1016/0140-6736(93)92411-L
  7. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy requiring autologous haemopoietic stem cell transplantation for relapsed chemosensitive Hodgkin’s disease: A randomised trial. Lancet. 2002;359(9323):2065–71. doi: 10.1016/S0140-6736(02)08938-9. DOI: https://doi.org/10.1016/S0140-6736(02)08938-9
  8. Passweg JR, Baldomero H, Chabannon C, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 2021;56(7):1651–64. doi: 10.1038/s41409-021-01227-8. DOI: https://doi.org/10.1038/s41409-021-01227-8
  9. Passweg JP, Baldomero H, Atlija M, et al. The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT. Bone Marrow Transplant. 2025;60(4):519–28. doi: 10.1038/s41409-025-02524-2. DOI: https://doi.org/10.1038/s41409-025-02524-2
  10. Frei E 3rd, Teicher BA, Holden SA, Wang YY. Preclinical studies and clinical correlation of the effect of the alkylating dose. Cancer Res. 1988;48(22): 6417–23.
  11. Teicher BA, Holden SA, Eder JP, et al. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. Cancer Res. 1989;49(21):5994–8.
  12. Martínez C, Boumendil A, Romejko-Jarosinska J, et al. Second autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma after a previous autograft: a study of the lymphoma working party of the EBMT. Leuk Lymphoma. 2020;61(12):2915–22. doi: 10.1080/10428194.2020.1789624. DOI: https://doi.org/10.1080/10428194.2020.1789624
  13. Smith EP, Li H, Friedberg JW, et al. Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). Biol Blood Marrow Transplant. 2018;24(4):700–7. doi: 10.1016/j.bbmt.2017.12.798. DOI: https://doi.org/10.1016/j.bbmt.2017.12.798
  14. Tarella C, Cuttica A, Vitolo U, et al. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the Intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence. Cancer. 2003;97(11):2748–59. doi: 10.1002/cncr.11414. DOI: https://doi.org/10.1002/cncr.11414
  15. Vriesendorp HM. Aims of the conditioning. Exp Hematol. 2003;31(10):844–54. doi: 10.1016/s0301-472x(03)00229-7. DOI: https://doi.org/10.1016/S0301-472X(03)00229-7
  16. Jagannath S, Dicke KA, Armitage JO, et al. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin’s disease. Ann Intern Med. 1986;104(2):163–8. doi: 10.7326/0003-4819-104-2-163. DOI: https://doi.org/10.7326/0003-4819-104-2-163
  17. Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2006;12(10):1065–72. doi: 10.1016/j.bbmt.2006.06.006. DOI: https://doi.org/10.1016/j.bbmt.2006.06.006
  18. Caballero MD, Rubio V, Rifon J, et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant. 1997;20(6):451–8. doi: 10.1038/sj.bmt.1700913. DOI: https://doi.org/10.1038/sj.bmt.1700913
  19. Sharma A, Kayal S, Iqbal S, et al. Comparison of BEAM vs. LEAM regimen in autologous transplant for lymphoma at AIIMS. Springerplus. 2013;2:489. doi: 10.1186/2193-1801-2-489. DOI: https://doi.org/10.1186/2193-1801-2-489
  20. Visani G, Malerba L, Stefani PM, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011;118(12):3419–25. doi: 10.1182/blood-2011-04-351924. DOI: https://doi.org/10.1182/blood-2011-04-351924
  21. Саржевский В.О., Самойлова А.А., Мельниченко В.Я. и др. Безопасность и эффективность схемы BeEAC в качестве режима кондиционирования перед трансплантацией аутологичных гемопоэтических стволовых клеток при рецидивах и рефрактерных формах лимфом. Клиническая онкогематология. 2020;13(2):185–92. doi: 10.21320/2500-2139-2020-13-2-185-192. [Sarzhevskii V.O., Samoilova A.A., Melnichenko V.Ya., et al. Safety and Efficacy of BeEAC as a Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Lymphomas. Clinical oncohematology. 2020;13(2):185–92. doi: 10.21320/2500-2139-2020-13-2-185-192. (In Russ)] DOI: https://doi.org/10.21320/2500-2139-2020-13-2-185-192
  22. Attal M, Canal P, Schlaifer D, et al. Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation. J Clin Oncol. 1994;12(1):141–8. doi: 10.1200/JCO.1994.12.1.141. DOI: https://doi.org/10.1200/JCO.1994.12.1.141
  23. Ramzi M, Mohamadian M, Vojdani R, et al. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol. Exp Clin Transplant. 2012;10(2):163–7. doi: 10.6002/ect.2011.0092. DOI: https://doi.org/10.6002/ect.2011.0092
  24. Tarella C, Zallio F, Caracciolo D, et al. High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity. Leukemia. 2001;15(2):256–63. doi: 10.1038/sj.leu.2402011. DOI: https://doi.org/10.1038/sj.leu.2402011
  25. Waheed F, Kancherla R, Seiter K, et al. High dose chemotherapy with thiotepa, mitoxantrone and carboplatin (TMJ) followed by autologous stem cell support in 100 consecutive lymphoma patients in a single centre: analysis of efficacy, toxicity and prognostic factors. Leuk Lymphoma. 2004;45(11):2253–9. doi: 10.1080/10428190410001723250. DOI: https://doi.org/10.1080/10428190410001723250
  26. Wilson WH, Jain V, Bryant G, et al. Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. J Clin Oncol. 1992;10(11):1712–22. doi: 10.1200/JCO.1992.10.11.1712. DOI: https://doi.org/10.1200/JCO.1992.10.11.1712
  27. Sakellari I, Gavriilaki E, Bouziana S, et al. BEAC (carmustine, etoposide, cytarabine, and cyclophosphamide) in autologous hematopoietic cell transplantation: a safe and effective alternative conditioning regimen for Hodgkin and non-Hodgkin lymphoma. Bone Marrow Transplant. 2019;54(6):921–3. doi: 10.1038/s41409-018-0395-y. DOI: https://doi.org/10.1038/s41409-018-0395-y
  28. Lancet JE, Rapoport AP, Brasacchio R, et al Autotransplantation for relapsed or refractory Hodgkin’s disease: long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant. 1998;22(3):265–71. doi: 10.1038/sj.bmt.1701325. DOI: https://doi.org/10.1038/sj.bmt.1701325
  29. Jaimovich G, Ostriz MBR, Castro M, et al. CBeV (cyclophosphamide, bendamustine and etoposide) pre-autotransplant conditioning in persons with lymphoma. Bone Marrow Transplant. 2020;55(1):265–7. doi: 10.1038/s41409-019-0528-y. DOI: https://doi.org/10.1038/s41409-019-0528-y
  30. Perz J B, Giles C, Szydlo R, et al. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin’s lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre. Bone Marrow Transplant. 2007;39(1):41–7. doi: 10.1038/sj.bmt.1705544. DOI: https://doi.org/10.1038/sj.bmt.1705544
  31. Sellner L, Boumendil A, Finel H, et al. Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT. Bone Marrow Transplant. 2016;51(2):212–8. doi: 10.1038/bmt.2015.273. DOI: https://doi.org/10.1038/bmt.2015.273
  32. Joffe E, Rosenberg D, Rozovski U, et al. Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin’s and non-Hodgkin’s B-cell lymphoma. Bone Marrow Transplant. 2018;53(1):29–33. doi: 10.1038/bmt.2017.205. DOI: https://doi.org/10.1038/bmt.2017.205
  33. Musso M, Scalone R, Marcacci G, et al. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. Bone Marrow Transplant. 2010;45(7):1147–53. doi: 10.1038/bmt.2009.318. DOI: https://doi.org/10.1038/bmt.2009.318
  34. Crump M, Smith AM, Brandwein J, et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin’s disease: importance of disease status at transplant. J Clin Oncol. 1993;11(4):704–11. doi: 10.1200/JCO.1993.11.4.704. DOI: https://doi.org/10.1200/JCO.1993.11.4.704
  35. Stewart DA, Guo D, Sutherland JA, et al. Single-agent high-dose melphalan salvage therapy for Hodgkin’s disease: cost, safety, and long-term efficacy. Ann Oncol. 1997;8(12):1277–9. doi: 10.1023/a:1008268027332. DOI: https://doi.org/10.1023/A:1008268027332
  36. Nieto Y, Gruschkus S, Valdez BC, et al. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis Haematologica. 2022;107(4):899–908. doi: 10.3324/haematol.2021.278311. DOI: https://doi.org/10.3324/haematol.2021.278311
  37. Wadehra N, Farag S, Bolwell B, et al. Long‐term outcome of Hodgkin disease patients following high‐dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation. Biol Blood Marrow Transplant. 2006;12(12):1343–9. doi: 10.1016/j.bbmt.2006.08.039. DOI: https://doi.org/10.1016/j.bbmt.2006.08.039
  38. Gutierrez-Delgado F, Holmberg L, Hooper H, et al. Autologous stem cell transplantation for Hodgkin’s disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen. Bone Marrow Transplant. 2003;32(3):279–85. doi: 10.1038/sj.bmt.1704110. DOI: https://doi.org/10.1038/sj.bmt.1704110
  39. Nademanee A, O’Donnell MR, Snyder DS, et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin’s disease: results in 85 patients with analysis of prognostic factors. Blood. 1995;85(5):1381–90. DOI: https://doi.org/10.1182/blood.V85.5.1381.bloodjournal8551381
  40. Colita A, Colita A, Bumbea H, et al. LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation. Front Oncol. 2019;9:892. doi: 10.3389/fonc.2019.00892. DOI: https://doi.org/10.3389/fonc.2019.00892
  41. William BM, Loberiza Jr FR, Whalen V, et al. Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2013;13(4):417–23. doi: 0.1016/j.clml.2013.03.009. DOI: https://doi.org/10.1016/j.clml.2013.03.009
  42. Puig N, Rubia J, Remigia MR, et al. Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma. 2006;47(8):1488–94. doi: 10.1080/10428190500527769. DOI: https://doi.org/10.1080/10428190500527769
  43. Ran Wu, Liyuan Ma. BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis. Cell Transplant. 2023;32:9636897231179364. doi: 10.1177/09636897231179364. DOI: https://doi.org/10.1177/09636897231179364
  44. Halacoglu A, Serefhanoglu S. A Retrospective Comparison of Mitoxantrone-Melphalan and BEAM Conditioning Regimens Before Autologous Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Lymphoma Patients. Indian J Hematol Blood Transfus. 2022;38(1):92–8. doi: 10.1007/s12288-021-01439-4. DOI: https://doi.org/10.1007/s12288-021-01439-4
  45. Gunes AK, Serin I, Demir I, et al. Comparison of Mitoxantrone-Melphalan and BEAM Conditioning Regimens in Patients with Lymphoma. Hematol Oncol Stem Cell Ther. 2022;15(4):201–7. doi: 10.1016/j.hemonc.2021.03.005. DOI: https://doi.org/10.1016/j.hemonc.2021.03.005
  46. Xiong YY, Wang J, Wang L, et al. Comparison of CEAC, BEAM and IEAC conditioning regimens followed by autologous stem cell transplantation in peripheral T-cell lymphoma patients. Sci Rep. 2022;12(1):14369. doi: 10.1038/s41598-022-18540-x. DOI: https://doi.org/10.1038/s41598-022-18540-x
  47. Singer S, Dean R, Zhao Q, et al. BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2019;25(6):1107–15. doi: 10.1016/j.bbmt.2019.01.032. DOI: https://doi.org/10.1016/j.bbmt.2019.01.032
  48. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol. 1989;7(11):1630–6. doi: 10.1200/JCO.1989.7.11.1630. DOI: https://doi.org/10.1200/JCO.1989.7.11.1630
  49. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244. doi: 10.1200/JCO.1999.17.4.1244. DOI: https://doi.org/10.1200/JCO.1999.17.4.1244
  50. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–86. doi: 10.1200/JCO.2006.09.2403. DOI: https://doi.org/10.1200/JCO.2006.09.2403
  51. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–68. doi: 10.1200/JCO.2013.54.8800. DOI: https://doi.org/10.1200/JCO.2013.54.8800
  52. Younes A, Hilden P, Coiffier B, et al. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol. 2017;28(7):1436–47. doi: 10.1093/annonc/mdx097. DOI: https://doi.org/10.1093/annonc/mdx097
  53. Злокачественные новообразования в России в 2023 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2024. [Kaprin A.D., Starinskii V.V., Shakhzadova A.O., eds. Zlokachestvennye novoobrazovaniya v Rossii v 2023 godu (zabolevaemost’ i smertnost’). (Malignant neoplasms in Russia in 2023: incidence and mortality.) Moscow: MNIOI im. P.A. Gertsena — filial FGBU “NMITs radiologii” Publ.; 2024. (In Russ)]
  54. Kim JW, Lee HJ, Yi HG, et al. Mitoxantrone, etoposide, cytarabine, and melphalan (NEAM) followed by autologous stem cell transplantation for patients with chemosensitive aggressive non-Hodgkin lymphoma. Am J Hematol. 2012;87(5):479–83. doi: 10.1002/ajh.23150. DOI: https://doi.org/10.1002/ajh.23150
  55. Mollee P, Gupta V, Song K, et al. Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemia. Bone Marrow Transplant. 2004;33(12):1201–8. doi: 10.1038/sj.bmt.1704506. DOI: https://doi.org/10.1038/sj.bmt.1704506
  56. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis. Bone Marrow Transplant. 2001;28(10):909–15. doi: 10.1038/sj.bmt.1703260. DOI: https://doi.org/10.1038/sj.bmt.1703260
  57. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling. Bone Marrow Transplant. 2001;28(11):1001–11. doi: 10.1038/sj.bmt.1703271. DOI: https://doi.org/10.1038/sj.bmt.1703271
  58. Sureda A, Stavrik SG, Boumendil A, et al. Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT. Bone Marrow Transplant. 2020;55(11):2170–9. doi: 10.1038/s41409-020-0929-y. DOI: https://doi.org/10.1038/s41409-020-0929-y
  59. Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853–62. doi: 10.1016/S0140-6736(15)60165-9. DOI: https://doi.org/10.1016/S0140-6736(15)60165-9
  60. Vély A, Couturier MA, Delepine P, et al. Comparison of efficacy and toxicity according to etoposide and cytarabine dosing in BEAM conditioning followed by autologous stem cell transplantation in Hodgkin lymphoma. Leuk Lymphoma. 2023;64(13):2178–87. doi: 10.1080/10428194.2023.2251073. DOI: https://doi.org/10.1080/10428194.2023.2251073
  61. Sureda A, Arranz R, Iriondo A, et al. Autologous stem-cell transplantation for Hodgkin’s disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group. J Clin Oncol. 2001;19(5):1395–404. doi: 10.1200/JCO.2001.19.5.1395. DOI: https://doi.org/10.1200/JCO.2001.19.5.1395
  62. Marouf A, Molinari N, Sibon D, et al. Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA. Br J Haematol. 2023;202(2):379–83. doi: 10.1111/bjh.18859. DOI: https://doi.org/10.1111/bjh.18859
  63. Nieto Y, Valdez BC, Thall PF, et al. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer. 2016;122(17):2680–8. doi: 10.1002/cncr.30100. DOI: https://doi.org/10.1002/cncr.30100
  64. Nieto Y, Ramdial J, Valdez B, et al. Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma. Clin Cancer Res. 2025;31(6):975–82. doi: 10.1158/1078-0432.CCR-24-3544. DOI: https://doi.org/10.1158/1078-0432.CCR-24-3544

Keywords:

relapsed/refractory course, classical Hodgkin lymphoma, high-dose chemotherapy regimens, autologous hematopoietic stem cell transplantation

License

Copyright (c) 2026 Clinical Oncohematology. Basic Research and Clinical Practice

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.

For Contact

  • Galina Dmitrievna Petrova, MD, PhD, NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522, e-mail: galina_petrova@bk.ru

Downloads

Published

01.10.2026

Issue

Vol. 19 No. 4 (2026)
BONE MARROW TRANSPLANTATION

How to Cite

Petrova G.D., Monin I.S., Zolotaikina N.M., et al. Conditioning Regimens Prior to Autologous Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma. Clinical Oncohematology. Basic Research and Clinical Practice. 2026;19(4):443–452. doi:10.21320/2500-2139-2026-19-4-443-452.

Most read articles by the same author(s)

1 2 3 4 > >>